Cell-free DNA for the detection of fetal aneuploidy

Tamar Goldwaser, Susan D. Klugman

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Screening for fetal aneuploidy via cell-free DNA was described more than two decades ago and has been used clinically by obstetric providers in the United States for more than 5 years. Cell-free DNA affords excellent detection of fetal Down syndrome and other common aneuploidies and thus is sought by patients and providers. However, owing to the source of the DNA and the nature of the screening test, scenarios may arise that require expert counseling about complex issues regarding fetal and maternal health, test interpretation, and management. It is essential that infertility specialists understand the specific issues related to the strengths and limitations of this screening test, especially in light of expanded genetic testing of embryos.

Original languageEnglish (US)
Pages (from-to)195-200
Number of pages6
JournalFertility and Sterility
Volume109
Issue number2
DOIs
StatePublished - Feb 1 2018

Fingerprint

Aneuploidy
DNA
Genetic Testing
Down Syndrome
Infertility
Obstetrics
Counseling
Embryonic Structures

Keywords

  • Aneuploidy
  • cell-free DNA
  • prenatal

ASJC Scopus subject areas

  • Reproductive Medicine
  • Obstetrics and Gynecology

Cite this

Cell-free DNA for the detection of fetal aneuploidy. / Goldwaser, Tamar; Klugman, Susan D.

In: Fertility and Sterility, Vol. 109, No. 2, 01.02.2018, p. 195-200.

Research output: Contribution to journalReview article

Goldwaser, Tamar ; Klugman, Susan D. / Cell-free DNA for the detection of fetal aneuploidy. In: Fertility and Sterility. 2018 ; Vol. 109, No. 2. pp. 195-200.
@article{a2fbe99699fd439b81910573367d0e70,
title = "Cell-free DNA for the detection of fetal aneuploidy",
abstract = "Screening for fetal aneuploidy via cell-free DNA was described more than two decades ago and has been used clinically by obstetric providers in the United States for more than 5 years. Cell-free DNA affords excellent detection of fetal Down syndrome and other common aneuploidies and thus is sought by patients and providers. However, owing to the source of the DNA and the nature of the screening test, scenarios may arise that require expert counseling about complex issues regarding fetal and maternal health, test interpretation, and management. It is essential that infertility specialists understand the specific issues related to the strengths and limitations of this screening test, especially in light of expanded genetic testing of embryos.",
keywords = "Aneuploidy, cell-free DNA, prenatal",
author = "Tamar Goldwaser and Klugman, {Susan D.}",
year = "2018",
month = "2",
day = "1",
doi = "10.1016/j.fertnstert.2017.12.019",
language = "English (US)",
volume = "109",
pages = "195--200",
journal = "Fertility and Sterility",
issn = "0015-0282",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Cell-free DNA for the detection of fetal aneuploidy

AU - Goldwaser, Tamar

AU - Klugman, Susan D.

PY - 2018/2/1

Y1 - 2018/2/1

N2 - Screening for fetal aneuploidy via cell-free DNA was described more than two decades ago and has been used clinically by obstetric providers in the United States for more than 5 years. Cell-free DNA affords excellent detection of fetal Down syndrome and other common aneuploidies and thus is sought by patients and providers. However, owing to the source of the DNA and the nature of the screening test, scenarios may arise that require expert counseling about complex issues regarding fetal and maternal health, test interpretation, and management. It is essential that infertility specialists understand the specific issues related to the strengths and limitations of this screening test, especially in light of expanded genetic testing of embryos.

AB - Screening for fetal aneuploidy via cell-free DNA was described more than two decades ago and has been used clinically by obstetric providers in the United States for more than 5 years. Cell-free DNA affords excellent detection of fetal Down syndrome and other common aneuploidies and thus is sought by patients and providers. However, owing to the source of the DNA and the nature of the screening test, scenarios may arise that require expert counseling about complex issues regarding fetal and maternal health, test interpretation, and management. It is essential that infertility specialists understand the specific issues related to the strengths and limitations of this screening test, especially in light of expanded genetic testing of embryos.

KW - Aneuploidy

KW - cell-free DNA

KW - prenatal

UR - http://www.scopus.com/inward/record.url?scp=85042037169&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042037169&partnerID=8YFLogxK

U2 - 10.1016/j.fertnstert.2017.12.019

DO - 10.1016/j.fertnstert.2017.12.019

M3 - Review article

C2 - 29447662

AN - SCOPUS:85042037169

VL - 109

SP - 195

EP - 200

JO - Fertility and Sterility

JF - Fertility and Sterility

SN - 0015-0282

IS - 2

ER -